Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
Lifestyle changes (diet, exercise, weight loss) are the mainstay of NAFLD/NASH management; vitamin E and some medications may help, but always consult your doctor.
ESAs reduce total heart failure hospitalizations and improve hemoglobin and exercise tolerance, but do not lower first hospitalization or mortality risk.
Yes, gene modulation is a promising experimental approach for liver fibrosis and MASH, with several strategies showing preclinical success, though human treatments are not yet…
Nanotechnology shows promise for treating liver fibrosis by delivering drugs directly to liver cells, improving how treatments work, and reducing side effects compared to…
Machine learning models analyze patient data to predict liver fibrosis with moderate accuracy, often outperforming traditional tests like FIB-4, but they are not yet standard in…
Specific genetic variants in the PON1 gene can change how well the enzyme works, which directly influences a person's risk for developing liver fibrosis and related metabolic…
New antifibrotic therapies focus on reprogramming immune cells like macrophages and using metabolic drugs that reduce liver fat, rather than just targeting scar tissue directly.
Yes, recent studies show parenteral treprostinil can improve outcomes in children with PAH, though evidence is from observational studies, not large trials.
Yes, the drug Winrevair (sotatercept) improves exercise capacity in adults with pulmonary arterial hypertension by increasing distance walked and oxygen use.
Yes, rituximab can cause serum sickness in patients with immune thrombocytopenia (ITP), with cases documented in both children and adults.
Yes, MRAs reduce nonfatal heart events in dialysis patients but raise risks of high potassium and breast tenderness; talk to your doctor about the balance.
Pharmacist-led interventions improve medication management, adherence, and toxicity control in hematological malignancies, though effects on survival and hospitalization are less…
Screening nulliparous women involves checking blood pressure, urine, and uterine artery blood flow to find those at risk, followed by low-dose aspirin to prevent preeclampsia and…
Yes, mepolizumab can help patients with asthma who also have nasal polyps by reducing polyp size, improving symptoms, and lowering exacerbation risk.
Anti-IL-5 drugs like mepolizumab and tezepelumab improve symptoms and smell in chronic rhinosinusitis with nasal polyps, though surgery often adds extra benefit.
Yes, biologics significantly improve quality of life in severe nasal polyps by reducing symptoms, need for steroids, and surgery, with benefits seen in smell, congestion, and…
Smell improvement from tezepelumab begins within days and continues to grow over 52 weeks of treatment.
Yes, tezepelumab significantly improves sense of smell and taste in adults with chronic rhinosinusitis with nasal polyps, with benefits seen as early as one week and sustained…
Going to a hospital with higher cardiac capability significantly lowers the risk of death for patients with cardiogenic shock compared to lower-tier facilities.
An IABP may improve survival chances in advanced cardiogenic shock, but results are mixed and depend on the patient's specific condition.
Delivering CAR T-cells directly into the tumor or brain ventricles significantly lowers severe side effects compared to giving them through the bloodstream for high-grade glioma…
Yes, observational studies suggest pulmonary artery catheter use is linked to lower in-hospital mortality in cardiogenic shock, but randomized trials are lacking.
AI shows potential for risk stratification and treatment support in cardiogenic shock, but real-world use in the ER remains limited by data quality and implementation challenges.
After standard surgery and radiation, high-grade glioma most often returns in the center of the original tumor area or just at the edge of the radiation field.
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.